Chronic enteropathy clinical study details (dogs).
Locations.
- Southfield, MI
- Blaine, MN
Study details.
Our Southfield, MI hospital, in conjunction with Royal Canin and WALTHAM, is conducting a study to determine the effect of dietary regulation on canine patients with chronic enteropathy. This study will also potentially provide insight into biomarkers of canine GI disease.
Pets will receive lab work at no cost to the owner, including CBC, serum chemistry, urinalysis, and a fecal screening for Cryptosporidium, Giardia, and Clostridium enterotoxin. Additionally, the initial consultation, recheck consults, abdominal ultrasound and study diet will be provided at no charge to the owner.
Study eligibility.
Inclusion criteria include:
- Adult dogs ≥ 1 year of age (all breeds and sexes will be considered)
- Body weight 3 –70 kg
- History of chronic diarrhea and/or vomiting for ≥ 4 weeks
- Dogs with either intermittent or continuous (daily) clinical signs may be included
- Small bowel disease and/or large bowel disease may be included
Exclusion criteria include:
- Other causes of GI upset or concurrent disease on screening: Animals with a low serum cobalamin will be treated with oral or parenteral supplementation (according to the attending internal medicine veterinarian’s preference) but will not be excluded based on this finding alone.
- Dogs with a diagnosis of a protein losing enteropathy (PLE), based on screening
- Pregnant or lactating
- Medications
o Short-acting corticosteroid therapy within the 2 weeks before enrollment
o Long-acting corticosteroid therapy within 6 weeks before enrollment
o Current medications or supplements that cannot be discontinued during the
study period
o Some medications (such as heartworm preventative) may be continued if adjusted to a form that does not provide any confounding protein antigens
Michigan participation.
Contact Dr. Jessica Romine or Dr. Caitlin Barry-Heffernan at 248.354.6640.
Minnesota participation.
Contact Samantha Haberman, CVT, at 763.754.5000.
